8-K: Phio Pharmaceuticals Secures $0.48 Million in Registered Direct Offering and Private Placement

Phio Pharmaceuticals has successfully priced a registered direct offering and concurrent private placement, raising approximately $0.48 million to support working capital.

Summary

• Phio Pharmaceuticals Corp. has entered into a securities purchase agreement for a registered direct offering and concurrent private placement.
• The company will sell 240,000 shares of common stock at $2.00 per share in the registered direct offering.
• In a concurrent private placement, the company will issue unregistered warrants to purchase up to 240,000 shares of common stock.
• Each warrant is exercisable for one share of common stock at an exercise price of $2.00 per share and expires five years from the date of issuance.
• The net proceeds from the offering and private placement are estimated to be approximately $0.48 million, after deducting fees and expenses.
• The company has agreed to register the warrant shares for resale within 30 calendar days and use commercially reasonable efforts to have the registration statement declared effective within 60 calendar days.
• The company is restricted from issuing further common stock or convertible securities until January 8, 2025, and from variable rate transactions until December 23, 2025, with some exceptions.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. The company has successfully raised capital, but there are restrictions on future equity issuances and the offering was priced at $2.00 per share, which may be below the current market price. The company is also obligated to register the warrant shares for resale, which may create additional administrative burden.

Positives

• The company has successfully raised additional capital to support its operations.
• The warrants provide potential for future capital if exercised.
• The company has a clear timeline for registering the warrant shares for resale.

Negatives

• The company is restricted from certain equity issuances for a period of time.
• The offering was priced at $2.00 per share, which may be below the current market price.
• The company is obligated to register the warrant shares for resale, which may create additional administrative burden.

Risks

• The company's ability to achieve the registration of the warrant shares within the specified timeframe is not guaranteed.
• The restrictions on future equity issuances could limit the company's financial flexibility.
• The exercise of warrants is not guaranteed and depends on market conditions and investor sentiment.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The company is also obligated to register the warrant shares for resale and to seek effectiveness of the registration statement.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company to fund ongoing research and development activities. The use of a registered direct offering and concurrent private placement is a common approach to raise capital while minimizing market impact.

Comparison to Industry Standards

• The offering size of $0.48 million is relatively small compared to larger biotech companies, but is typical for a company of Phio's size and stage.
• The use of warrants in a private placement is a common practice to incentivize investors.
• The restrictions on future equity issuances are standard in such agreements to protect investors from dilution.
• The requirement to register the warrant shares for resale is a standard practice to provide liquidity to investors.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Investors in the offering will receive shares and warrants.
• The company will have additional working capital to support its operations.

Next Steps

• The company will close the offering on or about December 24, 2024.
• The company will file a prospectus supplement with the SEC.
• The company will register the warrant shares for resale within 30 calendar days.
• The company will use commercially reasonable efforts to have the registration statement declared effective within 60 calendar days.
• The company will apply to list the shares and warrant shares on the Nasdaq Capital Market.

Key Dates

Keywords

registered direct offering, private placement, common stock, warrants, capital raise, securities purchase agreement, biotechnology, INTASYL, gene silencing, immuno-oncology